BMY240719C42000
- 1.83
- +0.58+46.40%
Bristol-Myers Squibb Newsroom
Bristol Myers Squibb Validates Net-Zero Goals Through Science Based Targets Initiative
Bristol Myers Squibb (BMY) said Thursday it has validated its near-term and longer-term targets to lower greenhouse emissions throughout its value chain to net-zero by 2050 through the Science Based
Bristol-Myers Squibb Options Spot-On: On July 17th, 77,366 Contracts Were Traded, With 827.89K Open Interest
On July 17th ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 77,366 options for the day, of which put options accounted for 20.95% of the total
Big Pharma Rally After J&J Earnings
US Bancorp Posts Upbeat Earnings, Joins Aehr Test Systems, Hancock Whitney And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Wednesday.Shares of U.S. Bancorp (NYSE:USB) shares rose during Wednesday's session following a second-quarter earnings
Bristol-Myers Squibb Up Over 5%, on Pace for Largest Percent Increase Since November 2020 -- Data Talk
Bristol-Myers Squibb Company (BMY) is currently at $43.36, up $2.16 or 5.24% --Would be highest close since May 20, 2024, when it closed at $43.36 --On pace for largest percent increase since Nov. 4,
TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $45 From $67
Bristol-Myers Squibb (BMY) has an average hold rating and price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 41.17, Change: -0.03, Percent Change: -0.07
Bristol-Myers Squibb Insiders Sold US$1.1m Of Shares Suggesting Hesitancy
Express News | Bristol-Myers Squibb Co : TD Cowen Cuts Target Price to $45 From $67
Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained
Bristol-Myers Squibb (BMY) has an average hold rating and a price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 40.25, Change: +0.10, Percent Change: +0.25
Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
Bristol-Myers Squibb Unusual Options Activity For July 15
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 10 unusual trades.Delving into the details,
Bristol-Myers Squibb's Q2 2024 Earnings: What to Expect
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $52
Wells Fargo analyst Mohit Bansal maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 63.9%
Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $43
UBS analyst Trung Huynh maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $52 to $43.According to TipRanks data, the analyst has a success rate of 75.5%
Express News | Bristol-Myers Squibb Co : UBS Cuts Target Price to $43 From $47
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41
Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37
Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success